KNSA Stock Price, Kiniksa Pharmaceuticals Quote, Chart

Market Summary

USD20.22-0.04

Market Closed

-0.20%

KNSA Alerts

Big jump in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

KNSA Stock Price

View Fullscreen

KNSA RSI Chart

KNSA Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

165.11

Price/Sales (Trailing)

4.73

EV/EBITDA

-66.51

Price/Free Cashflow

66.85

KNSA Price/Sales (Trailing)

KNSA Profitability

EBT Margin

-7.15%

Return on Equity

2%

Return on Assets

1.66%

Free Cashflow Yield

1.5%

KNSA Fundamentals

KNSA Revenue

Revenue (TTM)

301.8M

Rev. Growth (Yr)

65.18%

Rev. Growth (Qtr)

-4.24%

KNSA Earnings

Earnings (TTM)

8.7M

Earnings Growth (Yr)

-44.29%

Earnings Growth (Qtr)

-170.15%

Breaking Down KNSA Revenue

Last 7 days

4.5%

Last 30 days

14.7%

Last 90 days

6.6%

Trailing 12 Months

47.4%

How does KNSA drawdown profile look like?

KNSA Financial Health

Current Ratio

4.21

KNSA Investor Care

Shares Dilution (1Y)

1.26%

Diluted EPS (TTM)

0.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	301.8M	0	0	0
2023	236.3M	280.8M	248.7M	270.3M
2022	84.0M	129.4M	174.8M	220.2M
2021	0	0	0	38.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kiniksa Pharmaceuticals Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	levy richard s	acquired	-	-	747	-
Apr 26, 2024	ragosa mark	sold (taxes)	-9,100	17.88	-509	chief financial officer
Apr 26, 2024	ragosa mark	acquired	-	-	991	chief financial officer
Apr 08, 2024	tessari eben	acquired	-	-	2,726	chief operating officer
Apr 08, 2024	patel sanj k	sold (taxes)	-72,942	17.9	-4,075	chairman & ceo
Apr 08, 2024	megna michael r	acquired	-	-	3,932	chief accounting officer
Apr 08, 2024	paolini john f.	acquired	-	-	2,497	chief medical officer
Apr 08, 2024	moat ross	acquired	-	-	2,477	chief commercial officer
Apr 08, 2024	ragosa mark	sold (taxes)	-14,158	17.9	-791	chief financial officer
Apr 08, 2024	tessari eben	sold (taxes)	-14,337	17.9	-801	chief operating officer

Which funds bought or sold KNSA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	new	-	144,905	144,905	-%
May 08, 2024	PROFUND ADVISORS LLC	added	38.63	155,897	434,573	0.02%
May 08, 2024	US BANCORP \DE\	new	-	2,289	2,289	-%
May 07, 2024	M&T Bank Corp	reduced	-0.21	78,464	716,850	-%
May 07, 2024	QRG CAPITAL MANAGEMENT, INC.	reduced	-5.2	18,647	299,462	-%
May 07, 2024	Swiss National Bank	unchanged	-	121,764	1,096,990	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	added	14.06	173,000	785,000	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	265	1,959,470	2,589,030	-%
May 07, 2024	SEI INVESTMENTS CO	new	-	1,449,790	1,449,790	-%
May 06, 2024	SG Americas Securities, LLC	added	8.1	67,000	378,000	-%

Are Funds Buying or Selling KNSA?

Are funds buying KNSA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KNSA

No. of Funds

Unveiling Kiniksa Pharmaceuticals Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	10.5%	4,192,446	SC 13G/A
Feb 14, 2024	fairmount funds management llc	8.1%	2,883,221	SC 13G/A
Feb 14, 2024	hhlr advisors, ltd.	9.9%	3,879,426	SC 13G/A
Feb 13, 2024	vanguard group inc	8.37%	2,965,299	SC 13G/A
Feb 12, 2024	rubric capital management lp	8.21%	2,907,501	SC 13G
Jan 25, 2024	blackrock inc.	9.0%	3,180,588	SC 13G
Aug 18, 2023	hhlr advisors, ltd.	9.9%	3,541,301	SC 13G/A
Aug 10, 2023	fairmount funds management llc	6.1%	2,143,052	SC 13G
Mar 08, 2023	blackrock inc.	4.9%	3,427,741	SC 13G/A
Feb 14, 2023	hhlr advisors, ltd.	7.6%	2,623,924	SC 13G/A

Recent SEC filings of Kiniksa Pharmaceuticals Ltd

View All Filings

Date Filed	Form Type	Document
May 07, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 25, 2024	10-Q	Quarterly Report
Apr 23, 2024	8-K	Current Report
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 10, 2024	PRE 14A	PRE 14A
Apr 08, 2024	4	Insider Trading

Peers (Alternatives to Kiniksa Pharmaceuticals Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	16.03%	-8.84%	-7.88	6.87	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.2B	2.0B	-2.41%	-26.73%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	-2.02%	101.31%	-9.84	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.8	394.93%	39.61%
AXSM	3.5B	251.0M	5.14%	-1.20%	-11.8	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.34	12.18	-1.03%	-92.09%
ACAD	2.5B	726.4M	-3.99%	-20.25%	-40.84	3.45	40.45%	71.62%
SMALL-CAP
CPRX	1.9B	411.3M	-5.16%	-15.46%	28.42	4.5	60.38%	-34.49%
NVAX	627.0M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	467.5M	881.7K	5.23%	376.44%	-13.85	481.06	-77.61%	33.36%
INO	260.8M	4.9M	-3.00%	9.13%	-1.93	53.59	-54.97%	51.71%
IBIO	6.4M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Kiniksa Pharmaceuticals Ltd News

Latest updates

Kiniksa Pharmaceuticals Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	-4.2%	79,858,000	83,395,000	67,046,000	71,473,000	48,345,000	61,884,000	99,135,000	26,972,000	32,189,000	22,142,000	12,095,000	7,704,000
S&GA Expenses	5.3%	38,682,000	36,739,000	34,468,000	29,175,000	29,045,000	27,215,000	24,677,000	23,841,000	22,218,000	22,741,000	20,759,000	21,848,000
R&D Expenses	31.3%	26,334,000	20,052,000	17,106,000	23,767,000	15,172,000	14,390,000	16,485,000	13,798,000	20,817,000	27,433,000	19,236,000	23,945,000
EBITDA Margin	-21.1%	-0.06	-0.05	-0.04	0.16	0.12	0.06	-0.17	-0.82	-1.52	-4.00	-	-
Income Taxes	115.0%	3,428,000	-22,787,000	5,356,000	-16,211,000	2,906,000	2,380,000	-177,358,000	716,000	1,925,000	279,000	-118,000	1,014,000
Earnings Before Taxes	-682.7%	-14,276,000	2,450,000	-8,499,000	-1,239,000	-9,364,000	6,841,000	46,735,000	-19,265,000	-23,285,000	-36,054,000	-30,662,000	-40,549,000
EBT Margin	-16.0%	-0.07	-0.06	-0.05	0.15	0.11	0.05	-0.18	-0.84	-1.56	-4.06	-	-
Net Income	-170.2%	-17,704,000	25,237,000	-13,855,000	14,972,000	-12,270,000	4,461,000	224,093,000	-19,981,000	-25,210,000	-36,333,000	-30,544,000	-41,563,000
Net Income Margin	-45.0%	0.03	0.05	-0.03	0.82	0.83	0.83	0.82	-0.87	-1.59	-4.10	-	-
Free Cashflow	-8.6%	3,903,000	4,269,000	16,970,000	-3,777,000	-4,291,000	-11,544,000	62,031,000	-8,075,000	-37,097,000	-19,135,000	-28,560,000	-38,842,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.3%	520	526	483	484	443	460	460	211	231	233	253	279	311	349	384	271	226	255	282	308	346
Current Assets	-2.1%	271	276	256	246	232	243	242	180	199	196	218	245	276	333	378	264	213	242	268	296	335
Cash Equivalents	30.7%	141	108	118	113	81.00	123	176	94.00	63.00	122	190	168	120	114	86.00	124	107	47.00	69.00	83.00	83.00
Inventory	-12.4%	27.00	31.00	26.00	24.00	23.00	22.00	15.00	20.00	13.00	4.00	6.00	6.00	2.00	-	-	-	-	-	-	-	-
Net PPE	-3.0%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00
Liabilities	0.3%	88.00	87.00	78.00	73.00	53.00	64.00	76.00	57.00	65.00	48.00	39.00	43.00	40.00	38.00	26.00	21.00	20.00	29.00	30.00	33.00	40.00
Current Liabilities	0.9%	64.00	64.00	53.00	47.00	37.00	47.00	56.00	44.00	50.00	45.00	34.00	39.00	35.00	32.00	25.00	21.00	19.00	28.00	28.00	30.00	37.00
Shareholder's Equity	-1.6%	432	439	405	412	390	396	384	153	166	185	214	236	271	312	359	250	206	225	252	275	307
Retained Earnings	-3.7%	-495	-477	-503	-489	-504	-492	-496	-720	-700	-675	-639	-608	-566	-517	-463	-419	-382	-356	-324	-297	-260
Additional Paid-In Capital	1.2%	928	917	908	901	894	888	881	874	867	860	853	844	838	829	822	670	588	581	576	572	567
Shares Outstanding	0.8%	71.00	70.00	70.00	70.00	70.00	69.00	69.00	69.00	69.00	69.00	69.00	68.00	68.00	62.00	60.00	57.00	55.00	54.00	54.00	54.00	52.00
Float	-	-	-	-	510	-	-	-	347	-	-	-	487	-	-	-	713	-	-	-	305	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-7.8%	3,987	4,325	16,986	-3,743	-4,267	-11,576	62,053	-7,824	-36,846	-18,884	-28,509	-38,783	-40,122	-41,191	-34,321	-29,224	-31,796	-24,170	-29,267	-41,676	-63,256
Share Based Compensation	-7.3%	7,206	7,773	6,788	6,473	6,115	6,372	6,041	6,676	6,031	6,131	6,199	5,717	7,126	6,257	5,558	4,851	4,209	4,965	3,758	3,464	2,893
Cashflow From Investing	271.4%	25,524	-14,894	-12,277	35,534	-37,920	-42,660	19,040	38,265	-22,723	-50,041	47,849	85,993	44,834	68,643	-149,660	-31,217	88,790	1,916	15,213	41,363	-9,278
Cashflow From Financing	419.9%	3,613	695	552	158	90.00	1,190	361	542	423	1,212	2,680	887	1,106	712	146,399	77,561	2,414	373	53.00	494	83,187

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KNSA Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 79,858	$ 48,345
Costs and operating expenses:
Cost of goods sold	10,583	7,036
Collaboration expenses	20,801	8,288
Research and development	26,334	15,172
Selling, general and administrative	38,682	29,045
Total operating expenses	96,400	59,541
Loss from operations	(16,542)	(11,196)
Other income	2,266	1,832
Loss before income taxes	(14,276)	(9,364)
Provision for income taxes	(3,428)	(2,906)
Net loss	$ (17,704)	$ (12,270)
Net loss per share attributable to common shareholders, basic	$ (0.25)	$ (0.18)
Net loss per share attributable to common shareholders, diluted	$ (0.25)	$ (0.18)
Weighted average common shares outstanding, basic	70,633,023	69,751,697
Weighted average common shares outstanding, diluted	70,633,023	69,751,697
Comprehensive loss:
Net loss	$ (17,704)	$ (12,270)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax	(59)	11
Total other comprehensive income (loss)	(59)	11
Total comprehensive loss	(17,763)	(12,259)
Product revenue, net
Revenue:
Revenue	78,885	42,659
License and collaboration revenue
Revenue:
Revenue	$ 973	$ 5,686

KNSA Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 141,078	$ 107,954
Short-term investments	72,474	98,417
Accounts receivable, net	15,995	21,266
Inventory	27,278	31,122
Prepaid expenses and other current assets	13,766	17,538
Total current assets	270,591	276,297
Property and equipment, net	712	734
Operating lease right-of-use assets	12,324	11,931
Other long-term assets	4,128	827
Intangible asset, net	17,000	17,250
Deferred tax assets	214,918	219,283
Total assets	519,673	526,322
Current liabilities:
Accounts payable	5,632	8,246
Accrued expenses	44,718	44,667
Deferred revenue	156	307
Operating lease liabilities	2,279	2,253
Other current liabilities	11,427	8,193
Total current liabilities	64,212	63,666
Non-current liabilities:
Non-current deferred revenue	11,811	11,954
Non-current operating lease liabilities	9,864	10,005
Other long-term liabilities	1,891	1,858
Total liabilities	87,778	87,483
Commitments and contingencies (Note 13)
Shareholders' equity:
Additional paid-in capital	927,582	916,763
Accumulated other comprehensive income (loss)	(53)	6
Accumulated deficit	(495,654)	(477,950)
Total shareholders' equity	431,895	438,839
Total liabilities and shareholders' equity	519,673	526,322
Class A common shares
Shareholders' equity:
Common stock value	11	10
Class B common shares
Shareholders' equity:
Common stock value	1	1
Class A1 common shares
Shareholders' equity:
Common stock value	4	5
Class B1 common shares
Shareholders' equity:
Common stock value	$ 4	$ 4

About Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

CEO	Mr. Sanj K. Patel
WEBSITE	kiniksa.com
INDUSTRY	Biotechnology
EMPLOYEES	220

Kiniksa Pharmaceuticals Ltd Frequently Asked Questions

What is the ticker symbol for Kiniksa Pharmaceuticals Ltd? What does KNSA stand for in stocks?

KNSA is the stock ticker symbol of Kiniksa Pharmaceuticals Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kiniksa Pharmaceuticals Ltd (KNSA)?

As of Wed May 08 2024, market cap of Kiniksa Pharmaceuticals Ltd is 1.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KNSA stock?

You can check KNSA's fair value in chart for subscribers.

What is the fair value of KNSA stock?

You can check KNSA's fair value in chart for subscribers. The fair value of Kiniksa Pharmaceuticals Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kiniksa Pharmaceuticals Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KNSA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kiniksa Pharmaceuticals Ltd a good stock to buy?

The fair value guage provides a quick view whether KNSA is over valued or under valued. Whether Kiniksa Pharmaceuticals Ltd is cheap or expensive depends on the assumptions which impact Kiniksa Pharmaceuticals Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KNSA.

What is Kiniksa Pharmaceuticals Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, KNSA's PE ratio (Price to Earnings) is 165.44 and Price to Sales (PS) ratio is 4.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KNSA PE ratio will change depending on the future growth rate expectations of investors.